Literature DB >> 28373187

AUC/MIC Pharmacodynamic Target Is Not a Good Predictor of Vancomycin Efficacy in Methicillin-Resistant Staphylococcus aureus Experimental Endocarditis.

Ximena Castañeda1, Cristina García-de-la-Mària2, Oriol Gasch3, Juan M Pericas2, Yolanda Armero2, Dolors Soy2, Javier García-González2, Carlos Falces2, Salvador Ninot2, Manel Almela2,4, Juan Ambrosioni2, Eduardo Quintana2, Barbara Vidal2, David Fuster2, Jaume Llopis5, Sara Soto4, Asuncion Moreno2, Francesc Marco2,4, Jose M Miró6.   

Abstract

The aim of this in vivo study was to compare the efficacy of vancomycin at standard doses (VAN-SD) to that of VAN at adjusted doses (VAN-AD) in achieving a VAN area under the curve/MIC ratio (AUC/MIC) of ≥400 against three methicillin-resistant Staphylococcus aureus (MRSA) strains with different microdilution VAN MICs in an experimental endocarditis model. The valve vegetation bacterial counts after 48 h of VAN therapy were compared, and no differences were observed between the two treatment groups for any of the three strains tested. Overall, for VAN-SD and VAN-AD, the rates of sterile vegetations were 15/45 (33.3%) and 21/49 (42.8%) (P = 0.343), while the medians (interquartile ranges [IQRs]) for log10 CFU/g of vegetation were 2 (0 to 6.9) and 2 (0 to 4.5) (P = 0.384), respectively. In conclusion, this VAN AUC/MIC pharmacodynamic target was not a good predictor of vancomycin efficacy in MRSA experimental endocarditis.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  MRSA; Staphylococcus aureus; experimental endocarditis; pharmacodynamic target; vancomycin MIC

Mesh:

Substances:

Year:  2017        PMID: 28373187      PMCID: PMC5444163          DOI: 10.1128/AAC.02486-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

Review 1.  Antibiotic resistance of bacteria in biofilms.

Authors:  P S Stewart; J W Costerton
Journal:  Lancet       Date:  2001-07-14       Impact factor: 79.321

Review 2.  Bacterial biofilms: a common cause of persistent infections.

Authors:  J W Costerton; P S Stewart; E P Greenberg
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

Review 3.  The pharmacokinetic and pharmacodynamic properties of vancomycin.

Authors:  Michael J Rybak
Journal:  Clin Infect Dis       Date:  2006-01-01       Impact factor: 9.079

4.  Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

Authors:  Vance G Fowler; Helen W Boucher; G Ralph Corey; Elias Abrutyn; Adolf W Karchmer; Mark E Rupp; Donald P Levine; Henry F Chambers; Francis P Tally; Gloria A Vigliani; Christopher H Cabell; Arthur Stanley Link; Ignace DeMeyer; Scott G Filler; Marcus Zervos; Paul Cook; Jeffrey Parsonnet; Jack M Bernstein; Connie Savor Price; Graeme N Forrest; Gerd Fätkenheuer; Marcelo Gareca; Susan J Rehm; Hans Reinhardt Brodt; Alan Tice; Sara E Cosgrove
Journal:  N Engl J Med       Date:  2006-08-17       Impact factor: 91.245

5.  High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.

Authors:  Levita K Hidayat; Donald I Hsu; Ryan Quist; Kimberly A Shriner; Annie Wong-Beringer
Journal:  Arch Intern Med       Date:  2006-10-23

6.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

7.  Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy.

Authors:  Nathalie Asseray; Cedric Jacqueline; Virginie Le Mabecque; Eric Batard; Denis Bugnon; Gilles Potel; Jocelyne Caillon
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

8.  Use of confocal microscopy to analyze the rate of vancomycin penetration through Staphylococcus aureus biofilms.

Authors:  Kimberly K Jefferson; Donald A Goldmann; Gerald B Pier
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

9.  Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia.

Authors:  T P Lodise; C D Miller; J Graves; A Evans; E Graffunder; M Helmecke; K Stellrecht
Journal:  J Antimicrob Chemother       Date:  2008-08-11       Impact factor: 5.790

10.  Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.

Authors:  José M Miró; Cristina García-de-la-Mària; Yolanda Armero; Elisa de-Lazzari; Dolors Soy; Asunción Moreno; Ana del Rio; Manel Almela; Carlos A Mestres; José M Gatell; María-Teresa Jiménez-de-Anta; Francesc Marco
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

View more
  3 in total

Review 1.  The Continued Value of Disk Diffusion for Assessing Antimicrobial Susceptibility in Clinical Laboratories: Report from the Clinical and Laboratory Standards Institute Methods Development and Standardization Working Group.

Authors:  Romney M Humphries; Susan Kircher; Andrea Ferrell; Kevin M Krause; Rianna Malherbe; Andre Hsiung; C A Burnham
Journal:  J Clin Microbiol       Date:  2018-07-26       Impact factor: 5.948

2.  Point-Counterpoint: Should Clinical Microbiology Laboratories Report Vancomycin MICs?

Authors:  Sara L Revolinski; Christopher D Doern
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

3.  Discordance of vancomycin minimum inhibitory concentration for methicillin-resistant Staphylococcus aureus at 2 μg/mL between Vitek II, E-test, and Broth Microdilution.

Authors:  Chien-Feng Kuo; Chon Fu Lio; Hsiang-Ting Chen; Yu-Ting Tina Wang; Kevin Sheng-Kai Ma; Yi Ting Chou; Fu-Chieh Chang; Shin-Yi Tsai
Journal:  PeerJ       Date:  2020-05-11       Impact factor: 2.984

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.